PETALING JAYA: The Russian Direct Investment Fund has signed a deal to supply the Sputnik V Covid-19 vaccine to Malaysia.
According to a spokesman from the Russian Embassy in Malaysia, it is understood that its sovereign wealth fund had signed the deal today with the health ministry.
However, no other details were provided. This is the third vaccine deal signed by Malaysia.
To date, the Sputnik V vaccine has been approved by several countries, including Argentina, Belarus and Serbia.
It was previously reported that the vaccine was developed by the Gamaleya Research Institute, which is part of Russia’s health ministry.
In December, Gamaleya announced that the vaccine had an efficacy level of 91.4%.
Meanwhile, Reuters reported that Duopharma, a Malaysian pharmaceutical firm, will supply 6.4 million doses of Gamaleya’s Sputnik V vaccine.
On Nov 24, Prime Minister Muhyiddin Yassin announced that the government had signed an agreement with Pfizer to procure 12.8 million doses of its Covid-19 vaccines, produced in collaboration with Germany’s BioNTech.
And on Jan 11, Putrajaya agreed to procure an additional 12.2 million doses of vaccine produced by Pfizer-BioNTech.
Pharmaniaga Bhd also signed an agreement with China’s Sinovac earlier this month to purchase ready-to-fill Covid-19 vaccines and later to manufacture the vaccine domestically.
CLICK HERE FOR OUR LIVE UPDATE OF THE COVID-19 SITUATION IN MALAYSIA
We are live on Telegram, subscribe here for breaking news and the latest announcements.